Targeted paclitaxel prodrug nanoassemblies to improve therapeutic effects for liver cancer

Qin, Shasha; Li, Jiamin; Pan, Zhiling; Wang, Can; Zhang, Bingfeng

doi:10.1016/j.colsurfb.2023.113285

Cited by 4 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a significant challenge lies in the fact that Paclitaxel-induced autophagy may lead to resistance to the drug’s own anticancer properties [ 46 , 47 ]. Recent research has shed light on potential solutions, indicating that the inhibition of autophagic processes in tumor cells can restore sensitivity to Paclitaxel, and that encapsulating Paclitaxel with nanoparticles or liposomes may enhance its anticancer effects [ 48 – 50 ]. These insights align with the findings of our study, where resistance to Paclitaxel is more marked in the high-risk HCC population.…”

Section: Discussionmentioning

confidence: 99%

Developing risk models and subtypes of autophagy-associated LncRNAs for enhanced prognostic prediction and precision in therapeutic approaches for liver cancer patients

ZHANG,

CHU,

2024

View full text Add to dashboard Cite

Background Limited research has been conducted on the influence of autophagy-associated long non-coding RNAs (ARLncRNAs) on the prognosis of hepatocellular carcinoma (HCC). Methods We analyzed 371 HCC samples from TCGA, identifying expression networks of ARLncRNAs using autophagy-related genes. Screening for prognostically relevant ARLncRNAs involved univariate Cox regression, Lasso regression, and multivariate Cox regression. A Nomogram was further employed to assess the reliability of Riskscore, calculated from the signatures of screened ARLncRNAs, in predicting outcomes. Additionally, we compared drug sensitivities in patient groups with differing risk levels and investigated potential biological pathways through enrichment analysis, using consensus clustering to identify subgroups related to ARLncRNAs. Results The screening process identified 27 ARLncRNAs, with 13 being associated with HCC prognosis. Consequently, a set of signatures comprising 8 ARLncRNAs was successfully constructed as independent prognostic factors for HCC. Patients in the high-risk group showed very poor prognoses in most clinical categories. The Riskscore was closely related to immune cell scores, such as macrophages, and the DEGs between different groups were implicated in metabolism, cell cycle, and mitotic processes. Notably, high-risk group patients demonstrated a significantly lower IC50 for Paclitaxel, suggesting that Paclitaxel could be an ideal treatment for those at elevated risk for HCC. We further identified C2 as the Paclitaxel subtype, where patients exhibited higher Riskscores, reduced survival rates, and more severe clinical progression. Conclusion The 8 signatures based on ARLncRNAs present novel targets for prognostic prediction in HCC. The drug candidate Paclitaxel may effectively treat HCC by impacting ARLncRNAs expression. With the identification of ARLncRNAs-related isoforms, these results provide valuable insights for clinical exploration of autophagy mechanisms in HCC pathogenesis and offer potential avenues for precision medicine.

show abstract